Abstract: A system, method for determining blood biomarkers implemented by a processor and memory circuitry (PMC) and a program storage device and computer program product which includes providing near infra-red spectrogram data i of a patient's living tissue; using one or more pre-trained prediction models comprising a selected number of prediction routes, and determining prediction data on a selected group of biomarkers; determining one or more biomarkers associated with a number of groups, and determining an average concentration data of said biomarkers in accordance with output data of a number of prediction routes associated with said number of groups; and generating output data indicative of estimated levels of a selected set of biomarkers for said patient.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.

Abstract: The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

Abstract: The present invention identifies biomarkers that are diagnostic of neural injury, neuronal disorder or neurotoxicity and is related to the discovery that proteases are selectively activated in subjects suffering from nervous system damage as compared to healthy subjects. Breakdown products reflecting protease activation are produced and detection of these different biomarkers of the invention is also diagnostic of the degree of severity and type of nerve damage in a subject.

Abstract: Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological fluids after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (CSF). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological samples after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (biological samples). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: An immobilizing device for biological material comprises a rigid support (12) carrying a substrate layer (20, 20?) of polymer having biological immobilizing properties, e.g. for amino and nucleic acids. Substantially solid ultra-thin substrate layers (20?) having a thickness less than about 5 micron, preferably between about 0.1 and 0.5 micron, and micro-porous, ultra-thin substrate layers (20?) having a thickness less than about 5 micron, preferably less than 3 micron, 2 or 1 micron are shown, which may be segmented by isolating moats M. The substrate layer is on a microscope slide (302), round disc (122), bio-cassette, at the bottom of a well of a multiwell plate, and as a coating inside a tube. Fluorescence or luminescence intensity and geometric calibration spots (420) are shown. Reading is enhanced by the intensity calibration spots (420) to enable normalization of readings under uneven illumination conditions, as when reading by dark field, side illumination mode.

Abstract: An immobilizing device for biological material comprises a rigid support (12) carrying a substrate layer (20, 20?) of polymer having biological immobilizing properties, e.g. for amino and nucleic acids. Substantially solid ultra-thin substrate layers (20?) having a thickness less than about 5 micron, preferably between about 0.1 and 0.5 micron, and micro-porous, ultra-thin substrate layers (20?) having a thickness less than about 5 micron, preferably less than 3 micron, 2 or 1 micron are shown, which may be segmented by isolating moats M. The substrate layer is on a microscope slide (302), round disc (122), bio-cassette, at the bottom of a well of a multiwell plate, and as a coating inside a tube. Fluorescence or luminescence intensity and geometric calibration spots (420) are shown. Reading is enhanced by the intensity calibration spots. (420) to enable normalization of readings under uneven illumination conditions, as when reading by dark field, side illumination mode.

Abstract: A support for an array of fluorescently labeled samples comprises a transparent body defining: (a) an array-support surface and (b) under the support surface, in spaced apart relationship thereto, a field of embedded optical features exposed to be illuminated by a broad light beam of excitation radiation addressed to the support from a predetermined general direction selected to produce a surface wave effect at the support surface, the field of embedded optical features and the support being so constructed that light of the beam incident on the features is launched through the support at an angle to the support surface that produces the surface wave effect of radiation in the manner that it can produce fluorescence from the labeled samples to be imaged beyond the support from a direction different from the direction of the illumination.